WEKO3
アイテム
Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs
https://az.repo.nii.ac.jp/records/2000427
https://az.repo.nii.ac.jp/records/200042737bc402a-daec-46b2-b6f6-2bff8567f67b
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
2025 SGLT2 inhibitor (JVMS).pdf (1.8 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2025-04-16 | |||||
| タイトル | ||||||
| タイトル | Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| Abstract | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Human pharmaceuticals are widely used in veterinary medicine. Nevertheless, identifying the optimal pharmaceuticals and dosages has been a significant challenge, as these medications may not be efficacious or may even be toxic to small animals. Following the approval of a pharmaceutical for human use, comprehensive non-clinical information is made public in Japan as Summary Technical Documentation (STED) and in the U.S. as Drug Approval Packages. As canines are often employed in non-clinical investigations, the information could prove invaluable in identifying the optimal pharmaceuticals and dosages. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a class of anti-diabetic agents for humans, with a total of nine drugs currently approved in Japan, the U.S. and the E.U. Among them, dapagliflozin and empagliflozin have been approved for the treatment of chronic heart failure. In canines, myxomatous mitral valve disease (MMVD) represents the most prevalent etiology of chronic heart failure. Despite the recommendation of pimobendan and loop diuretics as standard-of-care medications, MMVD remains a disease with a poor prognosis due to its progressive nature. We examined the pharmacology, safety, and pharmacokinetics of the globally approved SGLT2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) in canines in the STED. Based on these results, we propose dapagliflozin as the most favorable pharmaceutical in canines. We also discuss the potential effects of SGLT2 inhibitors on canine MMVD, considering the similarities between canine MMVD and human chronic heart failure. | |||||
| 言語 | en | |||||
| bibliographic_information |
巻 87, 号 6, p. 647-666 |
|||||
| 出版者 | ||||||
| 出版者 | The Japanese Society of Veterinary Science | |||||
| 言語 | en | |||||
| item_10002_relation_14 | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1292/jvms.25-0040 | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| item_1730428627434 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 査読あり | |||||
